Research programme: neurodegenerative disorder therapeutics - Axxam/Sanofi

Drug Profile

Research programme: neurodegenerative disorder therapeutics - Axxam/Sanofi

Latest Information Update: 08 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Axxam
  • Developer Axxam; Sanofi
  • Class Neuroprotectants; Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Research Neurodegenerative disorders

Most Recent Events

  • 05 Sep 2017 Axxam and Sanofi agree to co-research and develop therapeutics for neurodegenerative disorders
  • 05 Sep 2017 Early research in Neurodegenerative disorders in France, Italy (unspecified route) before September 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top